Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0476089 (endometrial cancer)
 11,379 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

This review discusses recent papers on endometrial carcinoma variants, immunohistochemical studies, and prognostic indicators. The aggressive nature of uterine papillary serous carcinoma is confirmed, even in the absence of myometrial or vascular invasion, with a comprehensive review of the histology, clinical presentation, and proposed treatment protocols. The possible etiologic role of radiation in the development of uterine papillary serous carcinoma is alluded to. The virulence of endometrial carcinomas with trophoblastic differentiation, endometrial carcinomas with a malignant giant cell component, and clear cell carcinomas of the endometrium is documented. A series of immunohistochemical studies is presented suggesting that uterine carcinosarcomas are metaplastic carcinomas derived from a common stem cell and that a shared histogenesis of endometrial stromal tumors and uterine mesoderm exists. Immunohistochemical techniques may clarify diagnostic problems of uterine tumors and their metastases and differentiate mucinous tumors of endometrium from endocervical origin. Staining of both carcinoembryonic antigen and ferritin in neoplastic endometria may be helpful in their differentiation from hyperplasias in curettage specimens. Significant prognosticators in endometrial carcinoma are depth of myometrial invasion and lymphovascular space involvement with greatest prognostic information provided by the depth of myometrial invasion above DNA index.
 ...
PMID:Malignant endometrial pathology. 150 78

Serum ferritin concentrations of 50 normal women and 90 patients with neoplasms of female genital tract were determined by radioimmunoassay. The mean value of serum ferritin in 23 cases of ovarian carcinoma was 402.04 micrograms/L, significantly higher than that of normal subjects and patients with benign genital neoplasms. Serum ferritin levels in patients with endometrial carcinoma, endometrial stromal sarcoma, and benign genital neoplasms were significantly higher than that of the normal subjects. There was a positive correlation between the serum ferritin level and the clinical stage of ovarian carcinoma. The serum ferritin determination is useful in the diagnosis, differential diagnosis and prognosis of ovarian cancers.
 ...
PMID:[Evaluation of serum ferritin in female genital neoplasms]. 184 98

The distribution of carcinoembryonic antigen (CEA) and ferritin was demonstrated by immunohistochemical method in 95 patients with normal, hyperplastic, and neoplastic endometrium in order to distinguish among these conditions. Fifteen patients with normal endometrium (NE), 28 with hyperplasia (AH), 12 with atypical hyperplasia (AAH), and 40 with endometrial carcinoma (CA) were studied. Paraffin section tissues were subjected to immunostaining according to the avidin-biotin complex method. CEA was found in 33% of NE cases, 46% of AH, 75% of AAH, and 83% of CA (P less than 0.01). Ferritin was not detected in any case of NE; however, it was detected in one case (4%) of AH, in one case (8%) of AAH, and in 88% of CAs (P less than 0.001). Both tumor markers exhibited a heterogeneous staining pattern, and for a given histologic hyperplastic or malignant lesion, corresponded to several phenotypes. There was no significant correlation between clinical stage or tumor grade and CEA or ferritin expression. In conclusion, ferritin seems to be a better biological marker than CEA in distinguishing between hyperplastic and neoplastic endometrial lesions and it is also more reliable than CEA for endometrial malignancy since it was absent in normal and hyperplastic endometria.
 ...
PMID:Expression of carcinoembryonic antigen and ferritin in normal, hyperplastic, and neoplastic endometrium. 186 94

Blood serum levels of ferritin and trophoblastic globulin were measured by immunoassay in 389 and 114 cases, respectively, suffering malignant or benign tumors of the uterus and ovary as well as in controls. Hyperferritinemia identified at serum ferritin levels in excess of 200 micrograms/l was established in 94% of cases of ovarian cancer, 57%--benign ovarian tumors, 60%--endometrial carcinoma and in 16% of patients with uterine myoma. Patients with ovarian and uterine malignancies were shown to have the highest serum ferritin levels. The study failed to establish an increase in trophoblastic globulin concentration in cases of nontrophoblastic tumors of the genitals. It is suggested that serum ferritin level be measured in patients presenting with ovarian and uterine tumors and in subjects at high risk for ovarian cancer to assure early diagnosis of disease.
 ...
PMID:[Serum ferritin and trophoblastic globulin in genital tumors in women]. 218 Feb 8

We studied the pretreatment serum levels of 6 tumor markers in gynecological patients with and without malignant disease. The tumor markers were carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA), ferritin, Schwangerschaftsprotein 1 (SP1), Schwangerschaftsprotein 3 (SP3) and cancer antigen 125 (CA125). The results were as follows: (1) Serum CA125 and TPA levels were raised in 81% and 57% of patients with ovarian serous cystadenocarcinoma; CEA and SP3, in 52% and 43% respectively of patients with ovarian mucinous cystadenocarcinoma; CA125, TPA and SP3, in 76%, 48% and 48% respectively of patients with other ovarian malignancies; and TPA and SP3, in 56% and 40% respectively of patients with endometrial carcinoma. (2) Serum levels of TPA, ferritin and CA125 were more often raised with advancing stages of malignant disease. (3) Serum TPA levels were elevated in 55% of patients with stage I endometrial carcinoma, and serum SP3 levels were elevated in 35% of patients with a stage I malignant ovarian neoplasm and in 45% of patients with endometrial carcinoma. (4) One of the 6 tumor markers showed a raised level in 84% of patients with gynecologic malignancy as against 56% in those with benign gynecologic diseases.
 ...
PMID:Serum levels of six tumor markers in patients with benign and malignant gynecological disease. 340 Oct 42

Ferritin levels in extracts of tumor tissue and serum of patients with gynecological malignancies were assayed by immunodiffusion methods using a standard system of testing for ferritin. A high blood-ferritin level (500-1,000 ng/ml) was found in 8 out 21 patients with ovarian cancer, 8 out of 24 patients with endometrial carcinoma. 2 out of 8 cases of mucinous cystadenoma and in 2 out of 4 cases of pyoovarium. It was lower in other malignancies of the female genital tract. There was no correlation between the ferritin level of blood serum and that of tumor tissue extracts. Although blood serum ferritin was found in very few healthy subjects (2.5%), it is suggested that blood-ferritin level test should be carried out in the course of examination of slowly-progressing purulent adnexitis and mass screening for tumors of female genitals.
 ...
PMID:[Ferritin study in tumors of the female genitalia]. 640 1